Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Gilead's Newer Tenofovir Patents

The company may have found a way to protect its newest HIV franchise for longer than anticipated, perhaps 10 years longer than it suggests in its 10-K (see p. 15), in both the US and EU.

Published
15 August 2017
From
Seeking Alpha
Mylan launches 3 HIV generics in Canada

Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

Published
11 August 2017
From
Drug Store News
In first, healthcare provider to subsidize HIV medication

The decision by Meuhedet to subsidize a generic version of the drug Truvada is set to drive a dramatic drop in prices for HIV medication. Under the new policy, Meuhedet patients were expected to pay NIS 300-500 ($83-$138) for the medication instead of the current cost of some NIS 2,100 ($580).

Published
08 August 2017
From
The Times of Israel
AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

Published
07 August 2017
From
Bloomberg
Government could end HIV transmission in Australia with just $32m year

A new plan developed by the Australian Federation of AIDS Organisations says the investment would not only prevent thousands of people contracting the virus but would also eventually deliver $2 billion of savings to the federal government's budget.

Published
07 August 2017
From
The Sydney Morning Herald
PrEP demand in England is rapidly accelerating – and most will want to join the trial

A survey of people currently using pre-exposure prophylaxis (PrEP) has found that PrEP use has rapidly accelerated in the last year, with more than half of those

Published
04 August 2017
By
Gus Cairns
Mylan to Provide Generic Truvada for U.K. Trial

The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

Published
03 August 2017
From
Wall Street Journal
NHS England announces world’s largest single PrEP implementation trial to prevent HIV infection

NHS England has today (Thursday 3 August) announced the start of a pioneering implementation trial to provide HIV prevention drugs to people at high risk of HIV infection. From September, pre-exposure prophylaxis (PrEP) will now be provided by the NHS through the initial three year trial to an estimated 10,000 people, in what will be the largest single study of its type in the world.

Published
03 August 2017
From
NHS England
Sexual health services 'at tipping point' in England

More funding is needed to cope with rising visits to clinics, English councils warn.

Published
03 August 2017
From
BBC Health
Q&A: How Swaziland got on track to contain the world's highest HIV prevalence

Dr. Velephi Okello arrived at last week's International AIDS Society Conference on HIV Science with big news. The deputy director of health services at Swaziland's ministry of health was presenting the findings from a new survey showing that the country — which has the highest adult HIV prevalence in the world — is on track toward epidemic control.

Published
01 August 2017
From
Devex
← First12345...622Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.